XM does not provide services to residents of the United States of America.
B
B

Biomarin

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. Constellation Brands, Ge Vernova, Republic Services

U.S. RESEARCH ROUNDUP-Constellation Brands, Ge Vernova, Republic Services Oct 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Brands, Ge Vernova and Republic Services, on Friday. HIGHLIGHTS * Constellation Brands Inc STZ.N : JP Morgan cuts target price to $293 from $307 * Diamondback Energy Inc FANG.O : Gerdes Energy Research cuts to neutral from buy * Ge Vernova GEV.N : HSBC cuts to hold from buy * R
B
P
G
L
R

Biomarin Pharmaceutical Inc Reaffirming Its Long-Term Financial Guidance And Outlook That It Presented During Investor Day

BRIEF-Biomarin Pharmaceutical Inc Reaffirming Its Long-Term Financial Guidance And Outlook That It Presented During Investor Day Sept 24 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : BIOMARIN PHARMACEUTICAL INC: REAFFIRMING ITS LONG-TERM FINANCIAL GUIDANCE AND OUTLOOK THAT IT PRESENTED DURING INVESTOR DAY Source text for Eikon: [ID:n0001193125-2
B

Ascendis Pharma slips after $300 mln share offering launch

BUZZ-Ascendis Pharma slips after $300 mln share offering launch ** U.S.-listed shares of Ascendis Pharma ASND.O down 4.3% at $142.50 in extended trading as co seeks equity raise ** Denmark-based biopharma announces $300 mln offering of American depositary shares (ADSs) ** JP Morgan, Morgan Stanley, Evercore and Goldman Sachs are jt bookrunners ** On Mon, ASND shares closed up ~17% at $139.57 after co said its achondroplasia therapy TransCon CNP met main goal in trial to treat dwarfism ** Shares
B
G
J

U.S. Aerovironment, Insulet, Viasat

U.S. RESEARCH ROUNDUP- Aerovironment, Insulet, Viasat Sept 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aerovironment, Insulet and Viasat, on Tuesday. HIGHLIGHTS * Aerovironment Inc AVAV.O : Raymond James cuts to market perform from outperform * Frontier Communications Parent Inc FYBR.O : JP Morgan cuts to neutral from overweight * Insulet Corp PODD.O : Piper Sandler raises target price to $285 from $230 * Relm
B
C
C
E
I
D

Ascendis rises on positive trial data for dwarfism therapy

BUZZ-Ascendis rises on positive trial data for dwarfism therapy ** U.S.-listed shares of Denmark-based Ascendis Pharma A71.F , ASND.O rise 17.3% to $139.88 ** ASND says its achondroplasia therapy TransCon CNP met its main goal by showing an average growth velocity of 5.89 cm/year vs 4.41 cm/year for a placebo in a trial ** Achondroplasia is a form
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.